Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein. Cellular proliferation and tumor formation by Bcr–Abl–expressing cells were specifically inhibited by this compound. In colony–forming assays of peripheral blood or bone marrow from patients with CML, there was a 92–98% decrease in the number of bcr–abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr–abl–positive leukemias.

[1]  B. Druker,et al.  Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. , 1994, The Journal of biological chemistry.

[2]  M. Heinrich,et al.  Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells. , 1994, The Journal of clinical investigation.

[3]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Greenberger,et al.  Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[5]  I. Smith,et al.  A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. , 1982, British Journal of Cancer.

[6]  Pascal Furet,et al.  Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411 , 1995, J. Comput. Aided Mol. Des..

[7]  C. Bloomfield,et al.  Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583 , 1993 .

[8]  N. Lydon,et al.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Sausville,et al.  Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. , 1994, Anti-cancer drugs.

[10]  J. Cleveland,et al.  Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. McCormick,et al.  Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Levitzki,et al.  Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors , 1988, Science.

[13]  A. Whetton,et al.  Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. , 1993, Cancer research.

[14]  G. Morgan,et al.  Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction. , 1990, Experimental hematology.

[15]  G. Daley,et al.  v-abl causes hematopoietic disease distinct from that caused by bcr-abl. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[17]  L. Meijer,et al.  cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF , 1988, Cell.

[18]  J. Goldman,et al.  Autografting in chronic myeloidleukaemia , 1994 .

[19]  A. Deisseroth,et al.  Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups , 1994, The Lancet.

[20]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[21]  G. Cattoretti,et al.  Selective growth response to IL‐3 of a human leukaemic cell line with megakaryoblastic features , 1988, British journal of haematology.

[22]  B. Druker,et al.  The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. , 1995, Leukemia.

[23]  R. Salgia,et al.  Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. , 1994, The Journal of biological chemistry.

[24]  A. Levitzki,et al.  Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. , 1993, Blood.

[25]  O. J. Dunn.  Multiple Comparisons Using Rank Sums , 1964 .

[26]  C. Heldin,et al.  Platelet-derived growth factor: mechanism of action and possible in vivo function. , 1990, Cell regulation.

[27]  B Calabretta,et al.  Lineage-specific requirement of c-abl function in normal hematopoiesis. , 1989, Science.

[28]  A. Levitzki,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.

[29]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Cannistra,et al.  Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. , 1990, Blood.

[31]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[32]  P. Martiat,et al.  Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines. , 1993, Blood.

[33]  N. Heisterkamp,et al.  Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. , 1991, Oncogene.

[34]  P. Leder,et al.  Differentiation in erythroleukemic cells and their somatic hybrids. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Sawyers,et al.  The nuclear tyrosine kinase c-abl negatively regulates cell growth , 1994, Cell.

[36]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[37]  S. Smith,et al.  Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). , 1988, Science.

[38]  N. Lydon,et al.  4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[40]  Sante Tura,et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.

[41]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[42]  R. Salgia,et al.  Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. , 1993, Experimental hematology.

[43]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[44]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[45]  R. Weichselbaum,et al.  Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents , 1995, Nature.

[46]  J. Stephenson,et al.  Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia , 1983, Nature.

[47]  J. Goldman,et al.  Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Y. Honma,et al.  Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. , 1989, Cancer research.

[49]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.

[50]  S. Goff,et al.  Mice homozygous for the abl m1 mutation show poor viability and depletion of selected B and T cell populations , 1991, Cell.